<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT2017030132837N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2017-04-20</date_registration>
      <primary_sponsor>Vice chanceler for research, Iran university of medical sciences</primary_sponsor>
      <public_title>Comparison of the effect of Ketamine and Dexamethasone in combination with Lidocaine on the onset and duration of Axillary block in soft tissue surgery of forearm and hand</public_title>
      <acronym></acronym>
      <scientific_title>Comparison of the effect of Ketamine and Dexamethasone in combination with Lidocaine on the onset and duration of Axillary block in soft tissue surgery of forearm and hand</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2016-12-21</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>78</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/25485</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment.</study_design>
      <phase>N/A</phase>
      <hc_freetext>Soft tissue injury of forearm and hand.</hc_freetext>
      <i_freetext>Intervention 1: The intervention group 1 : Axillary block with 38 cc lidocaine 1%  in combination with dexamethasone 8 mg in 2 ml. Intervention 2: The intervention group 2 :   Axillary block with 38 cc Lidocaine 1% combination with 50 mg of Ketamine in 2 cc. Intervention 3: Control group : &#13;
Axillary block with 38 cc lidocaine 1%  in combination with 2 mL of saline.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan></results_IPD_plan>
      <results_IPD_description></results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Dr Behrooz Zaman</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>23 St, Asad abadi St, Tehran</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1433933111</zip>
        <telephone>+98 21 8871 0099</telephone>
        <email>behroozzaman@gmail.com  &#13;
 zaman.b@iums.ac.ir</email>
        <affiliation>Hazrat Fatemeh Hospital</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Dr Behrooz Zaman</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>23 St,Asad abadi St, Tehran</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1433933111</zip>
        <telephone>+98 21 8871 0099</telephone>
        <email>behroozzaman@gmail.com   zaman.b@iums.ac.ir</email>
        <affiliation>Hazrat Fatemeh Hospital</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Inclusion criteria:  Consent to participate in research project and cooperation for axillary block; No addiction to opium, Benzodiazepine, Clonidine;  Absence of liver and kidney failure, diabetes, cardiovascular and lung diseases, coagulopathy; Lack of any allergic history to local anesthetics; No use of opium in the past 48 hours; Absence of anatomical deformity or burning or infection in block region; No pregnancy in female patients.&#13;
 Exclusion criteria: The unwillingness or lack of cooperation from the patient during surgery.</inclusion_criteria>
      <agemin>20 years</agemin>
      <agemax>50 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria></exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>S50, S51, </hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Superficial injury of forearm, Open wound of forearm, Injury of nerves at forearm level,Injury of blood vessels at forearm level,  Injury of muscle and tendon at forearm level, Superficial injury of wrist and hand, Open wound of wrist and hand, Injury of </hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Other</i_code>
      <i_code>Other</i_code>
      <i_code>Other</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>The intervention group 1 : Axillary block with 38 cc lidocaine 1%  in combination with dexamethasone 8 mg in 2 ml</i_keyword>
      <i_keyword>The intervention group 2 :   Axillary block with 38 cc Lidocaine 1% combination with 50 mg of Ketamine in 2 cc</i_keyword>
      <i_keyword>Control group : &#13;
Axillary block with 38 cc lidocaine 1%  in combination with 2 mL of saline</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Onset of sensory block. Timepoint: every 3 minutes. Method of measurement: Measuring the length of time between the last injection until complete disappearance of any sense of touch with the stopwatch.</prim_outcome>
      <prim_outcome>Onset of motor block. Timepoint: every 3 minutes. Method of measurement: Measuring the length of time between the last injection to complete motor paralysis with Stopwatch.</prim_outcome>
      <prim_outcome>Duration of sensory block. Timepoint: every 3 minutes. Method of measurement: Measuring the time between onset of complete sensory block until the complete return again sense organs with Stopwatch.</prim_outcome>
      <prim_outcome>Duration of motor block. Timepoint: every 3 minutes. Method of measurement: Measuring the time between onset of complete paralysis to return of complete movement power with stopwtch.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Diastolic blood pressure. Timepoint: 0, 5, 10, 15, 20, 25 minutes after Axillary block. Method of measurement: Non-invasive automatic sphygmomanometer.</sec_outcome>
      <sec_outcome>Systolic blood pressure. Timepoint: 0, 5, 10, 15, 20, 25 minutes after Axillary block. Method of measurement: Non-invasive automatic sphygmomanometer.</sec_outcome>
      <sec_outcome>Pulse rate. Timepoint: 0, 5, 10, 15, 20, 25 minutes after Axillary block. Method of measurement: ECG monitoring.</sec_outcome>
      <sec_outcome>Nystagmus. Timepoint: 0, 5, 10, 15, 20, 25 minutes after Axillary block. Method of measurement: Find the rapid movements of the eyes of horizontal reciprocating.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Vice chanceler for research, Iran university of medical sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2016-04-05</approval_date>
        <contact_name>Iran University of Medical Sciences Ethics Committee</contact_name>
        <contact_address>Iran University of Medical Sciences, Hemmat Highway, Tehran Tehran  Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
